International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Jan 2005
Repeat radiosurgery for idiopathic trigeminal neuralgia.
Although frequently performed, the efficacy and safety of repeat trigeminal neuralgia radiosurgery is not well described. ⋯ Repeat trigeminal neuralgia radiosurgery at the dosage described has better facial pain outcomes than primary radiosurgery. However, because the procedure is nonselective and the rate of bothersome numbness was relatively high (16%), dose reduction is recommended to reduce the morbidity of repeat trigeminal neuralgia radiosurgery.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jan 2005
Dosimetry and cancer control after low-dose-rate prostate brachytherapy.
To describe the relationship between two commonly used dosimetric quantifiers (dose received by 90% of the prostate [D(90)] and volume receiving 100% of dose [V(100)]) and biochemical disease-free survival (bDFS) in a cohort of men treated with low-dose-rate prostate brachytherapy (LDRPB). ⋯ The dosimetric or quantifiers described in this report did not predict for bRFS after LDRPB unless the dosimetry was very poor. This finding is not in complete agreement with those of previous reports. Possible reasons for this observation are (1) the study in underpowered, (2) inherent measurement error, (3) dosimetric quantifiers are poor surrogates of the dose received by the cancer, and (4) length of follow-up. Additional work in the area of quality assessment after LDRPB is required.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jan 2005
Clinical TrialCisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
To fit the situation of developing countries, where supportive care is not sufficient, a modified combined therapy of cisplatin/etoposide (EP) and hyperfractionated accelerated radiation therapy (HART) was conducted as a Phase II trial for limited-stage small-cell lung cancer (LSCLC) to evaluate the feasibility, toxicity, and tolerance of the combined therapy and to observe its efficacy and patterns of failure. ⋯ The study led to the following conclusions: (1) LSCLC patients tolerate HART at 56 Gy in 40 fractions over 4 weeks combined with 6 cycles of EP chemotherapy. (2) Both control of the tumor in the thorax and survival appear superior to conventional fractionated radiation but not as good as that in a study by Turrisi and colleagues. (3) This modified chemoradiation schedule could be recommended to LSCLC patients in developing countries. (4) The lessons learned from our study are (a) higher radiation doses may be needed for better locoregional control, and (b) prophylactic cranial irradiation is necessary for LSCLC patients who show complete response.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jan 2005
Comparative StudyThe effect of an endorectal balloon and off-line correction on the interfraction systematic and random prostate position variations: a comparative study.
To investigate the effect of an endorectal balloon (ERB) and an off-line correction protocol on the day-to-day, interfraction prostate gland motion, in patients receiving external beam radiotherapy for prostate cancer. ⋯ The off-line corrections on the fiducial markers are effective in reducing the systematic prostate displacements. The investigated ERB does not reduce the interfraction prostate motion. Although the overall mean displacement is low, the day-to-day interfraction motion, especially in anterior-posterior direction, remains high compared with the systematic displacements.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jan 2005
Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein.
The role of HER-2/neu in the response of esophageal cancer to radiation is not well known. The purpose of this study was to evaluate the effect of an anti-HER-2/neu antibody trastuzumab on the proliferation, cell cycle distribution, and radiosensitivity of esophageal cancer cell lines. ⋯ This study suggested that trastuzumab plus irradiation may be effective for the treatment of esophageal cancers, including adenocarcinoma and squamous cell cancer with HER-2/neu expression.